

# CITATION REPORT

List of articles citing

**American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006**

**DOI: 10.1200/jco.2006.06.9591**

**Journal of Clinical Oncology, 2006, 24, 2932-47.**

**Source:** <https://exaly.com/paper-pdf/41130082/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
667	Evidence-based management of chemotherapy-induced nausea and vomiting: a position statement from a European cancer nursing forum. <b>2011</b> , 5, 211		13
666	Incidence of chemotherapy-induced nausea and vomiting in Mexico: healthcare provider predictions versus observed. <b>2006</b> , 22, 2403-10		27
665	Recent Publications on Medications and Pharmacy. <i>Hospital Pharmacy</i> , <b>2006</b> , 41, 899-904	1.1	
664	Docetaxel and Cisplatin (DP) Regimen for Solid Tumors. <i>Hospital Pharmacy</i> , <b>2006</b> , 41, 1032-1042	1.1	
663	Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC Followed by D) in the Treatment of Breast Cancer. <i>Hospital Pharmacy</i> , <b>2006</b> , 41, 1156-1163	1.1	
662	Palonosetron (Aloxi): a second-generation 5-HT <sub>3</sub> receptor antagonist for chemotherapy-induced nausea and vomiting. <b>2006</b> , 19, 413-6		27
661	Comparison of clinical efficacy of serotonin receptor antagonists in highly emetogenic chemotherapy. <b>2006</b> ,		1
660	Update on the management of chemotherapy-induced nausea and vomiting. <b>2006</b> , 29, 283-92		2
659	Controlling emesis: what is it worth?. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 5617; author reply 5616-7	2.2	2
658	In Reply. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 5616-5617	2.2	1
657	Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 4472-8	2.2	341
656	Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist. <b>2006</b> , 2, 591-602		25
655	In Reply. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 5616-5616	2.2	3
654	Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. <b>2007</b> , 12, 1143-50		147
653	Antiemetic care for patients with breast cancer: focus on drug interactions and safety concerns. <b>2007</b> , 64, 2227-36		9
652	Randomized crossover pharmacokinetic evaluation of subcutaneous versus intravenous granisetron in cancer patients treated with platinum-based chemotherapy. <b>2007</b> , 12, 1151-5		12
651	Quality of life for patients with epithelial ovarian cancer. <b>2007</b> , 4, 18-29		45

650	Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. <b>2007</b> , 99, 847-57	496
649	Cisplatin versus carboplatin for patients with metastatic non-small-cell lung cancer--an old rivalry renewed. <b>2007</b> , 99, 828-9	27
648	New anti-emetic treatments. <b>2007</b> , 18 Suppl 9, ix43-7	2
647	Management of intractable nausea and vomiting in patients at the end of life: "I was feeling nauseous all of the time . . . nothing was working". <b>2007</b> , 298, 1196-207	73
646	Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. <b>2007</b> , 18, 233-40	104
645	Are all 5-HT <sub>3</sub> receptor antagonists the same?. <b>2007</b> , 5, 35-43	14
644	Prevention of emesis from multiple-day and high-dose chemotherapy regimens. <b>2007</b> , 5, 51-9	42
643	Cancer Chemotherapy Update - Cisplatin, Doxorubicin, and High-dose Methotrexate for Osteosarcoma. <i>Hospital Pharmacy</i> , <b>2007</b> , 42, 702-710	1.1
642	Cytotoxic treatment-induced gastrointestinal symptoms. <b>2007</b> , 1, 16-22	13
641	Supportive care. <b>2007</b> , 2, 67-71	1
640	Managing treatment side effects in advanced breast cancer. <b>2007</b> , 23, S23-30	18
639	Novel therapeutic targets for enteric nervous system disorders. <b>2007</b> , 28, 473-81	49
638	A phase II study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer. <b>2007</b> , 43, 1153-60	19
637	Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan. <b>2007</b> , 29, 2256-67	37
636	Chinese medicinal herbs to treat the side-effects of chemotherapy in breast cancer patients. <i>The Cochrane Library</i> , <b>2007</b> , CD004921	5.2 49
635	Highlights from: The 24th Annual Miami Breast Cancer Conference; Miami, FL; March 14-17, 2007. <b>2007</b> , 4, 137-44	1
634	Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. <b>2007</b> , 16, 1977-85	36
633	Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. <b>2007</b> , 23, 533-43	141

632	The 5-HT <sub>3</sub> receptor as a therapeutic target. <b>2007</b> , 11, 527-40		185
631	Is there a need to identify new anti-emetic drugs?. <b>2007</b> , 4, 183-187		10
630	Cancer Chemotherapy Update: Mesna, Doxorubicin, Ifosfamide, and Dacarbazine (MAID) Regimen for Sarcomas. <i>Hospital Pharmacy</i> , <b>2007</b> , 42, 901-906	1.1	1
629	Radiation-induced nausea and vomiting. <b>2007</b> , 5, 60-5		14
628	Doxorubicin, Cisplatin, High-dose Methotrexate, and Ifosfamide for Osteosarcoma. <i>Hospital Pharmacy</i> , <b>2007</b> , 42, 801-811	1.1	1
627	Docetaxel and Carboplatin (DC) for Solid Tumors. <i>Hospital Pharmacy</i> , <b>2007</b> , 42, 27-33	1.1	
626	Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Prednisone (EPOCH) for Treatment of Lymphomas. <i>Hospital Pharmacy</i> , <b>2007</b> , 42, 1006-1012	1.1	
625	Neurokinin-1 receptor antagonists for prevention of chemotherapy-related nausea and vomiting in adults. <b>2007</b> ,		2
624	Preoperative hypnotherapy in the management of a child with anticipatory nausea and vomiting. <b>2007</b> , 35, 784-7		12
623	Docetaxel and Capecitabine (DC) Regimen for Solid Tumors. <i>Hospital Pharmacy</i> , <b>2007</b> , 42, 191-196	1.1	
622	[Nausea and vomiting in oncologic therapy. Guidelines for use of setrone]. <b>2007</b> , 36, 362-7		
621	[Prevention of nausea and vomiting. Aprepitant, the first therapeutic acting NK-1 receptor antagonist]. <b>2007</b> , 36, 373-80		0
620	Efficacy of injectable maropitant (Cerenia) in a randomized clinical trial for prevention and treatment of cisplatin-induced emesis in dogs presented as veterinary patients. <b>2007</b> , 5, 38-46		25
619	Anti-emetic therapy in cancer chemotherapy: current status. <b>2007</b> , 101, 143-50		56
618	Spécificité de la chimiothérapie chez le sujet âgé. <b>2007</b> , 9, 783-789		
617	The emerging role of cannabinoid neuromodulators in symptom management. <b>2007</b> , 15, 63-71		30
616	Differenzialdiagnose Nausea und Erbrechen. <b>2007</b> , 2, 201-211		0
615	Comparative activity of antiemetic drugs. <b>2007</b> , 61, 162-75		70

614	The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data. <b>2008</b> , 109, 559-66	40
613	Behandlung von medikamentenassoziierten Nebenwirkungen in der gynäkologischen Onkologie. <b>2008</b> , 41, 575-584	
612	Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment. <b>2008</b> , 62, 135-47	27
611	[Supportive care for malignant melanoma]. <b>2008</b> , 59, 492-8	1
610	[Clinical network structures in uro-oncology. A model for the future?]. <b>2008</b> , 47, 1128-32	1
609	Gastrointestinale Nebenwirkungen und Ernährung bei Tumorthherapie. <b>2008</b> , 14, 58-64	3
608	Early Austrian multicenter experience with palonosetron as antiemetic treatment for patients undergoing highly or moderately emetogenic chemotherapy. <b>2008</b> , 158, 169-73	6
607	Safety of ondansetron loading doses in children with cancer. <b>2008</b> , 16, 469-75	13
606	A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. <b>2008</b> , 16, 201-8	79
605	Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium. <b>2008</b> , 16, 905-15	32
604	Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II study. <b>2008</b> , 16, 1375-80	10
603	Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy. <b>2008</b> , 134, 1079-86	44
602	Application of distance matrices to define associations between acute toxicities in colorectal cancer patients receiving chemotherapy. <b>2008</b> , 112, 284-92	59
601	Beam path toxicities to non-target structures during intensity-modulated radiation therapy for head and neck cancer. <b>2008</b> , 72, 747-55	143
600	Nausea and vomiting. <b>2008</b> , 11, 135-44	10
599	Nausea and vomiting with high-dose chemotherapy and stem cell rescue therapy: a review of antiemetic regimens. <b>2008</b> , 42, 501-6	31
598	Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children. <b>2008</b> , 39, 601-6	46
597	The side effects of chemotherapeutic agents. <b>2008</b> , 19, 70-79	46

596	Review of acupressure studies for chemotherapy-induced nausea and vomiting control. <b>2008</b> , 36, 529-44	38
595	Intractable nausea in a patient with metastatic colorectal cancer following insertion of a colonic stent. <b>2008</b> , 36, e6-e10	3
594	Antiemetics: an update and the MASCC guidelines applied in clinical practice. <b>2008</b> , 5, 32-43	78
593	Aprepitant for the prevention of nausea and vomiting associated with chemotherapy and postoperative recovery. <b>2008</b> , 1, 27-37	2
592	Chemotherapy-induced nausea and vomiting. <b>2008</b> , 358, 2482-94	552
591	Palonosetron for prevention of acute and delayed nausea and vomiting induced by moderately emetogenic adjuvant folfox-4 regimen in colorectal cancer (CRC) patients: A phase II study of the Gruppo Oncologico dell' Italia Meridionale (GOIM). <b>2008</b> , 6, 102-106	5
590	Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. <b>2008</b> , 8, 1733-42	14
589	Le cancer broncho-pulmonaire non ^ petites cellules : point sur la pathologie et stratgie de d'cision thfapeutique. <b>2008</b> , 43, 93-102	
588	Breast Cancer 2nd edition. <b>2008</b> ,	1
587	Chemotherapy for Breast Cancer. <b>2008</b> , 345-385	1
586	Manejo general y extrahospitalario del paciente oncohematol'gico. <b>2008</b> , 10, 1429-1438	
585	[Managing nausea and vomiting in thoracic oncology]. <b>2008</b> , 64, 76-80	0
584	Administration du traitement m'dical en pratique (y compris facteurs de croissance). <b>2008</b> , 25, 3S151-3S159	
583	[Role of supportive care in lung cancer]. <b>2008</b> , 64, 118-24	1
582	Supportive care for women with gynecologic cancers. <b>2008</b> , 8, 227-41	18
581	Evolving roles of oncology pharmacists in Singapore: a survey on prescribing patterns of antiemetics for chemotherapy induced nausea and vomiting (CINV) at a cancer centre. <b>2008</b> , 14, 23-9	21
580	Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea. <b>2008</b> , 11, 261-7	49
579	Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain. <b>2008</b> , 17, 85-95	56

578	Management of metastatic germ cell tumors. <b>2008</b> , 8, 771-84		15
577	Evidence-based recommendations for cancer nausea and vomiting. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 3903-10	2.2	100
576	Gastrointestinal side effects associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board. <b>2008</b> , 12, 37-52		22
575	Chemotherapy-induced pica and anorexia are reduced by common hepatic branch vagotomy in the rat. <b>2008</b> , 294, R756-65		47
574	Effect of aprepitant on intravenous tacrolimus disposition in reduced intensity hematopoietic stem cell transplantation. <b>2008</b> , 14, 113-21		7
573	Cancer Supportive Care. <b>2008</b> ,		1
572	Principles of Safe Practice Using an Oncology EHR System for Chemotherapy Ordering, Preparation, and Administration, Part 2 of 2. <b>2008</b> , 4, 254-257		25
571	Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 1932-9	2.2	111
570	Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer. <b>2009</b> , 39, 111-5		5
569	Chemotherapy-induced nausea and vomiting. <b>2008</b> , 14, 85-93		80
568	Optimizing antiemetic therapy in multiple-day and multiple cycles of chemotherapy. <b>2008</b> , 2, 28-34		15
567	Clinical Update on Palonosetron in the Management of Chemotherapy-Induced Nausea and Vomiting. <b>2008</b> , 94, 447-452		8
566	A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting. <b>2008</b> , 4, 99-107		56
565	Cyclophosphamide, Vincristine, Doxorubicin and Dacarbazine (CYVADIC) for Soft Tissue Sarcomas. <i>Hospital Pharmacy</i> , <b>2008</b> , 43, 18-28	1.1	
564	Fluorouracil, Epirubicin, and Cyclophosphamide (FEC) for Breast Cancer. <i>Hospital Pharmacy</i> , <b>2008</b> , 43, 462-468	1.1	1
563	Irinotecan and Cisplatin (IP) Regimen. <i>Hospital Pharmacy</i> , <b>2008</b> , 43, 970-975	1.1	1
562	Ifosfamide, Carboplatin, and Etoposide (ICE) for Metastatic Soft Tissue Sarcoma. <i>Hospital Pharmacy</i> , <b>2008</b> , 43, 878-882	1.1	
561	Docetaxel, Cisplatin, and Fluorouracil (DCF) Regimen for Head, Neck, and Advanced Gastric Cancers. <i>Hospital Pharmacy</i> , <b>2008</b> , 43, 266-276	1.1	1

560	Cisplatin and Pemetrexed for Lung Cancer and Pleural Mesothelioma. <i>Hospital Pharmacy</i> , <b>2008</b> , 43, 800-805		
559	Vincristine, Dactinomycin, and Cyclophosphamide (VAC) Regimen. <i>Hospital Pharmacy</i> , <b>2008</b> , 43, 556-560	1.1	
558	Gemcitabine and Docetaxel (GD) for Advanced Soft Tissue Sarcomas. <i>Hospital Pharmacy</i> , <b>2008</b> , 43, 187-191		
557	Docetaxel and Estramustine for Prostate Cancer. <i>Hospital Pharmacy</i> , <b>2009</b> , 44, 473-478	1.1	
556	BEACOPP(escalated) Regimen for Hodgkin Lymphoma. <i>Hospital Pharmacy</i> , <b>2009</b> , 44, 858-865	1.1	
555	Lung Cancer in the Elderly. 237-247		
554	. <b>2009</b> ,		3
553	Palonosetron for the prevention of chemotherapy-induced nausea and vomiting: approval and efficacy. <i>Cancer Management and Research</i> , <b>2009</b> , Volume 1, 167-176	3.6	6
552	Antiemesis. Clinical Practice Guidelines in Oncology. <b>2009</b> , 7, 572-95		24
551	BEACOPP(baseline) Regimen for Hodgkin Lymphoma. <i>Hospital Pharmacy</i> , <b>2009</b> , 44, 662-669	1.1	1
550	Prevention of acute chemotherapy-induced nausea and vomiting: the role of palonosetron. <i>Cancer Management and Research</i> , <b>2009</b> , Volume 1, 89-97	3.6	2
549	Fluorouracil, Epirubicin, and Cyclophosphamide (FEC100) for Breast Cancer. <i>Hospital Pharmacy</i> , <b>2009</b> , 44, 26-31	1.1	3
548	[Guidelines for prophylaxis and treatment of chemotherapy-induced nausea and vomiting]. <i>Bulletin Du Cancer</i> , <b>2009</b> , 96, 951-60	2.4	12
547	Melphalan, Prednisone, and Thalidomide (MPT) Regimen for Multiple Myeloma. <i>Hospital Pharmacy</i> , <b>2009</b> , 44, 569-573	1.1	
546	Gemcitabine and Capecitabine (GemCap) Regimen for Solid Tumors. <i>Hospital Pharmacy</i> , <b>2009</b> , 44, 303-309	1.1	
545	Irinotecan and Carboplatin (IC) Regimen for Lung Cancer. <i>Hospital Pharmacy</i> , <b>2009</b> , 44, 740-745	1.1	
544	Use of granisetron transdermal system in the prevention of chemotherapy-induced nausea and vomiting: a review. <i>Cancer Management and Research</i> , <b>2009</b> , 1	3.6	4
543	Pemetrexed and Carboplatin (PC) Regimen. <i>Hospital Pharmacy</i> , <b>2009</b> , 44, 946-951	1.1	



542	Palonosetron Hydrochloride in the Treatment of Chemotherapy-Induced Nausea and Vomiting. <b>2009</b> , 1, CMT.S2179	
541	Casopitant: a novel NK(1)-receptor antagonist in the prevention of chemotherapy-induced nausea and vomiting. <b>2009</b> , 5, 375-84	9
540	Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant. <b>2009</b> , 5, 1607-14	18
539	Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide. <b>2009</b> , 43, 444-52	47
538	Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting. <b>2009</b> , 20, 1867-73	25
537	The Role of Supportive Therapy in the Era of Modern Adjuvant Treatment - Current and Future Tools. <b>2009</b> , 4, 167-176	4
536	Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development. <b>2009</b> , 16, 2661-805	59
535	A case of severe, refractory diabetic gastroparesis managed by prolonged use of aprepitant. <b>2009</b> , 5, 285-8	36
534	Chemotherapy-induced nausea and vomiting: challenges and opportunities for improved patient outcomes. <b>2009</b> , 13, 54-64	49
533	Chemotherapy-induced kaolin intake is increased by lesion of the lateral parabrachial nucleus of the rat. <b>2009</b> , 297, R1375-82	18
532	Chemotherapy agent cisplatin induces 48-h Fos expression in the brain of a vomiting species, the house musk shrew ( <i>Suncus murinus</i> ). <b>2009</b> , 296, R902-11	56
531	Capecitabine-based chemoradiotherapy with adjuvant capecitabine for locally advanced squamous carcinoma of the uterine cervix: phase II results. <b>2009</b> , 14, 828-34	17
530	Pharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy-induced nausea and vomiting. <b>2009</b> , 15, 223-31	30
529	A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy. <b>2009</b> , 20, 1860-6	43
528	Penny wise, dollar foolish approach to antiemetic use may compromise patient care. <b>2009</b> , 5, 221-2	3
527	A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy. <b>2009</b> , 20, 1874-80	22
526	Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy. <b>2009</b> , 115, 5807-16	27
525	Difficultés alimentaires liés à la chimiothérapie. <b>2009</b> , 11, 204-210	3

524	Neue Substanzen in der antiemetischen Therapie. <b>2009</b> , 15, 121-128	1
523	One third of patients with radiotherapy-induced nausea consider their antiemetic treatment insufficient. <b>2009</b> , 17, 23-32	61
522	Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy. <b>2009</b> , 17, 205-9	39
521	Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting. <b>2009</b> , 17, 563-72	117
520	Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. <b>2009</b> , 17, 589-94	66
519	Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide. <b>2009</b> , 17, 1065-70	18
518	Reduction of chemotherapy-induced anorexia, nausea, and emesis through a structured nursing intervention: a cluster-randomized multicenter trial. <b>2009</b> , 17, 1543-52	24
517	A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. <b>2009</b> , 113, 529-35	65
516	Abstracts of the ESCP 37th European Symposium on Clinical Pharmacy, Pharmaceutical Care Models, and Therapeutic Innovations. Dubrovnik, Croatia. October 21-24, 2008. <b>2009</b> , 31, 246-349	2
515	Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients. <b>2009</b> , 27, 173-8	16
514	Supportivtherapie in der Onkologie. <b>2009</b> , 4, 42-52	
513	Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. <b>2009</b> , 52, 242-7	72
512	In vitro and in vivo characteristics of prochlorperazine oral disintegrating film. <b>2009</b> , 368, 98-102	60
511	Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non elderly patient response. <b>2009</b> , 70, 83-91	26
510	Prevention of chemotherapy-induced nausea and vomiting in elderly cancer patients. <b>2009</b> , 71, 214-21	27
509	Acute and long-term gastrointestinal consequences of chemotherapy. <b>2009</b> , 23, 113-24	49
508	Current Clinical Management of Metastatic Lung Cancer. <b>2009</b> , 317-350	
507	American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 6251-66	2.2 619

506	Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist. <b>2009</b> , 5, 1577-86	16
505	Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy. <b>2009</b> , 45, 1184-1187	35
504	Preparation of a fast dissolving oral thin film containing dexamethasone: a possible application to antiemesis during cancer chemotherapy. <b>2009</b> , 73, 361-5	65
503	Brain Fos expression induced by the chemotherapy agent cisplatin in the rat is partially dependent on an intact abdominal vagus. <b>2009</b> , 148, 76-82	26
502	Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience. <b>2009</b> , 41, 3247-9	11
501	Polymorphism of human cytochrome P450 enzymes and its clinical impact. <b>2009</b> , 41, 89-295	579
500	Evidence for a re-evaluation of the neurochemical and anatomical bases of chemotherapy-induced vomiting. <b>2009</b> , 109, 3158-99	86
499	Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments. <b>2009</b> , 69, 515-33	65
498	Palonosetron: in the prevention of nausea and vomiting. <b>2009</b> , 69, 2257-78	54
497	Transdermal granisetron. <b>2009</b> , 69, 2597-605	16
496	Aprepitant: a review of its use in the prevention of nausea and vomiting. <b>2009</b> , 69, 1853-78	77
495	Cisplatin overdose: toxicities and management. <b>2009</b> , 32, 1109-22	139
494	Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting. <b>2009</b> , 28, 131	113
493	Ursolic acid triggers apoptosis and Bcl-2 downregulation in MCF-7 breast cancer cells. <b>2009</b> , 27, 723-33	95
492	Cost-effectiveness analysis of capecitabine compared with bolus 5-fluorouracil/l-leucovorin for the adjuvant treatment of colon cancer in Japan. <b>2009</b> , 27, 597-608	15
491	Antiemetic control: toward a new standard of care for emetogenic chemotherapy. <b>2009</b> , 10, 629-44	27
490	Data-driven medical decision-making in managing chemotherapy-induced nausea and vomiting. <b>2009</b> , 6, 62-67	8
489	Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. <b>2009</b> , 10, 115-24	336

488	Palonosetron: more than just another option?. <b>2009</b> , 10, 100-1	2
487	Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial. <b>2009</b> , 10, 549-58	60
486	Registrative trials of antiemetic drugs: arrival or starting point?. <b>2009</b> , 10, 533-4	1
485	Manejo general y extrahospitalario del paciente en tratamiento con quimioterapia y de sus complicaciones (2). <b>2009</b> , 10, 1687-1693	
484	The role of the primary care physician during the active treatment phase. <b>2009</b> , 36, 685-702	5
483	Omission of day 2 of antiemetic medications is a cost saving strategy for improving chemotherapy-induced nausea and vomiting control: results of a randomized phase III trial. <b>2009</b> , 32, 23-6	7
482	[The point where tumor chemotherapy comes into contact with palliative therapy]. <b>2009</b> , 98, 1952-8	
481	Obstacles to the implementation of antiemetic guidelines. <b>2009</b> , 7, 601-5	22
480	[Efficacy of preventive treatment for delayed emesis induced by FOLFOX4 chemotherapy]. <b>2009</b> , 129, 949-55	0
479	Evolution and elements of the quality oncology practice initiative measure set. <b>2009</b> , 16, 312-7	12
478	Aprepitant use in children, adolescents, and young adults for the control of chemotherapy-induced nausea and vomiting (CINV). <b>2010</b> , 32, e268-71	20
477	Standards for palliative care delivery in oncology settings. <b>2010</b> , 16, 436-43	8
476	[Pharmacological, pharmacokinetic, and clinical profile of palonosetron hydrochloride (ALOXI I.V. Injection 0.75 mg), a novel antiemetic 5-HT <sub>3</sub> -receptor antagonist]. <b>2010</b> , 136, 113-20	2
475	Chemotherapy-associated toxicity in a large cohort of elderly patients with non-small cell lung cancer. <b>2010</b> , 5, 90-8	27
474	Complications digestives des chimiothérapies. <b>2010</b> , 5, 1-15	
473	Prophylaxe des chimiothérapieinduzierten Erbrechen und der Übelkeit. <b>2010</b> , 13, 39-46	
472	Clonazepam use for prevention of acute and delayed vomiting induced by Cisplatin-based chemotherapy for lung cancer. <b>2010</b> , 33, 1907-10	1
471	Management of the gastrointestinal side effects of therapy in older adults with cancer. 400-418	

470	Evaluation of Usefulness of Pharmaceutical Outpatient Clinic for Cancer Patients. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , <b>2010</b> , 36, 85-98	0.1	14
469	Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. <b>2010</b> , 18, 423-31		191
468	Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. <b>2010</b> , 18, 1171-7		118
467	Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy. <b>2010</b> , 18, 1437-44		5
466	Management of chemotherapy-induced nausea and vomiting. <b>2010</b> , 47, 149-55		16
465	Supportive care for patients with early breast cancer. <b>2010</b> , 12, 32-42		2
464	SEOM clinical guidelines for the treatment of antiemetic prophylaxis in cancer patients receiving chemotherapy. <b>2010</b> , 12, 770-4		7
463	Chemotherapy Foundation Symposium XXVIII Innovative Cancer Therapy For Tomorrow Abstracts 2010. <b>2010</b> , 11, 1-104		6
462	Treatment-related symptoms among underserved women with breast cancer: the impact of physician-patient communication. <b>2010</b> , 119, 707-16		40
461	5-HT(3) receptors: role in disease and target of drugs. <b>2010</b> , 128, 146-69		161
460	[Analysis of the effectiveness of an antiemetic protocol used in an oncology division]. <b>2010</b> , 34, 125-38		3
459	Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors. <b>2010</b> , 119, 457-61		47
458	Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. <b>2010</b> , 70, 656-63		81
457	Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin. <b>2010</b> , 101, 2455-61		61
456	Anticipatory nausea among ambulatory cancer patients undergoing chemotherapy: prevalence, associated factors, and impact on quality of life. <b>2010</b> , 101, 2596-600		21
455	The efficacy of oral ondansetron and dexamethasone for the prevention of acute chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy - a retrospective audit. <b>2010</b> , 19, 403-7		2
454	Impact of quality of life parameters and coping strategies on postchemotherapy nausea and vomiting. <b>2010</b> , 19, 603-9		4
453	Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT. <b>2010</b> , 45, 123-7		26

452	Clinically-relevant chemotherapy interactions with complementary and alternative medicines in patients with cancer. <b>2010</b> , 2, 12-55	9
451	Bortezomib and Dexamethasone (BD) Regimen for Multiple Myeloma. <i>Hospital Pharmacy</i> , <b>2010</b> , 45, 33-37.1	
450	Docetaxel and Prednisone (DP) for Advanced Prostate Cancer. <i>Hospital Pharmacy</i> , <b>2010</b> , 45, 293-302	1.1
449	Polymorphism in HTR3D shows different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy. <b>2010</b> , 11, 943-50	24
448	Suicide associated with corticosteroid use during chemotherapy: case report. <b>2010</b> , 40, 174-6	6
447	Aprepitant: drug-drug interactions in perspective. <b>2010</b> , 21, 2316-2323	89
446	A randomized, double-blind, parallel, comparative study to evaluate the efficacy and safety of ramosetron plus dexamethasone injection for the prevention of acute chemotherapy-induced nausea and vomiting. <b>2010</b> , 40, 294-301	18
445	Effect of concord grape juice on chemotherapy-induced nausea and vomiting: results of a pilot study. <b>2010</b> , 37, 213-21	11
444	Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. <b>2010</b> , 21 Suppl 5, v232-43	502
443	Chemotherapy-induced nausea and vomiting: antiemetic trials that impacted clinical practice. <b>2010</b> , 16, 233-44	15
442	Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonist. <b>2010</b> , 50, 951-9	14
441	Review of palonosetron: emerging data distinguishing it as a novel 5-HT(3) receptor antagonist for chemotherapy-induced nausea and vomiting. <b>2010</b> , 11, 1003-14	14
440	Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer. <b>2010</b> , 6, 1073-84	29
439	Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX) Regimens plus Bevacizumab for Colorectal Cancer. <i>Hospital Pharmacy</i> , <b>2010</b> , 45, 685-693	1.1
438	Docetaxel, Cisplatin, and Fluorouracil (TCF) for Head and Neck Cancers. <i>Hospital Pharmacy</i> , <b>2010</b> , 45, 453-460	1.1
437	Epirubicin, Cisplatin, and Capecitabine (ECX) Regimen. <i>Hospital Pharmacy</i> , <b>2010</b> , 45, 527-533	1.1
436	Lapatinib and Capecitabine. <i>Hospital Pharmacy</i> , <b>2010</b> , 45, 762-767	1.1
435	Docetaxel and Carboplatin (DC) for Ovarian Cancer. <i>Hospital Pharmacy</i> , <b>2010</b> , 45, 607-613	1.1

434	Stanford V Regimen for Hodgkin Lymphoma. <i>Hospital Pharmacy</i> , <b>2010</b> , 45, 906-913		1.1
433	Food restriction, refeeding, and gastric fill fail to affect emesis in musk shrews. <b>2010</b> , 298, G25-30		13
432	Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. <b>2010</b> , 21, 1083-8		113
431	Management of chemotherapy-induced nausea and vomiting. <b>2010</b> , 65, 305-10		5
430	[Prevention, diagnosis, therapy, and follow-up of lung cancer]. <b>2010</b> , 64 Suppl 2, e1-164		85
429	Supporting Asian patients with metastatic breast cancer during ixabepilone therapy. <b>2010</b> , 9, 383-96		1
428	Pharmacokinetic evaluation of fosaprepitant dimeglumine. <b>2010</b> , 6, 1277-86		18
427	[Chemotherapy induced emesis: pathophysiology and prevention]. <i>Bulletin Du Cancer</i> , <b>2010</b> , 97, 233-43	2.4	5
426	[Prerequisites to the administration and prevention of adverse effects of chemotherapy in colorectal cancer]. <i>Bulletin Du Cancer</i> , <b>2010</b> , 97, 265-80	2.4	2
425	Approaches for administering chemotherapy in the intensive care unit. <b>2010</b> , 5, 22-32		8
424	Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting. <i>Core Evidence</i> , <b>2010</b> , 5, 77-90	4.9	26
423	Analysis of the effectiveness of an antiemetic protocol used in an oncology division. <b>2010</b> , 34, 125-138		1
422	Antiemetic therapy for nausea and vomiting in the emergency department. <b>2010</b> , 39, 330-6		38
421	Comorbidity and polypharmacy in elderly cancer patients: The significance on treatment outcome and tolerance. <b>2010</b> , 1, 87-102		24
420	Emesis and gastrointestinal problems during radiotherapy: a comparison of performance of daily activities between patients experiencing nausea and patients free from nausea. <b>2010</b> , 14, 359-66		7
419	Cost-utility analysis of palonosetron-based therapy in preventing emesis among breast cancer patients. <b>2010</b> , 8, 242-51		18
418	Incidence and risk factors for chemotherapy-induced nausea or vomiting following highly or moderately emetogenic chemotherapy in community oncology practice. <b>2010</b> , 7, 347-354		2
417	A prospective observational trial on emesis in radiotherapy: analysis of 1020 patients recruited in 45 Italian radiation oncology centres. <b>2010</b> , 94, 36-41		68

416	Intraperitoneal Therapy for Ovarian Cancer. <b>2010</b> ,		
415	Serotonin receptor antagonists for highly emetogenic chemotherapy in adults. <b>2010</b> , CD006272		32
414	Optimizing emetic control in children receiving antineoplastic therapy: beyond the guidelines. <b>2010</b> , 12, 51-61		22
413	Ondansetron dosing in pediatric gastroenteritis: a prospective cohort, dose-response study. <b>2010</b> , 12, 405-10		14
412	Clinical and economic burden of chemotherapy-induced nausea and vomiting among patients with cancer in a hospital outpatient setting in the United States. <b>2011</b> , 14, 87-98		33
411	Chemotherapy-induced nausea and vomiting and antiemetic prophylaxis with palonosetron versus other 5-HT <sub>3</sub> receptor antagonists in patients with cancer treated with low emetogenic chemotherapy in a hospital outpatient setting in the United States. <b>2011</b> , 27, 1613-22		5
410	Likelihood of a subsequent chemotherapy-induced nausea and vomiting (CINV) event in patients receiving low, moderately or highly emetogenic chemotherapy (LEC/MEC/HEC). <b>2011</b> , 27, 837-45		21
409	Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 1495-501	2.2	164
408	Update and new trends in antiemetic therapy: the continuing need for novel therapies. <b>2011</b> , 22, 30-38		92
407	Assessment and management of gastrointestinal symptoms in advanced illness. <b>2011</b> , 38, 225-46, viii		8
406	Essential drugs in supportive care. <b>2011</b> , 38, 413-23		0
405	Evaluation of stat orders in a teaching hospital: a chart review. <b>2011</b> , 31, 231-5		8
404	The MASCC Textbook of Cancer Supportive Care and Survivorship. <b>2011</b> ,		6
403	Advances in palliative medicine and end-of-life care. <b>2011</b> , 62, 187-99		16
402	Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. <b>2011</b> , 9, 188-95		203
401	A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation. <b>2011</b> , 43, 3107-10		22
400	Drug interactions in childhood cancer. <b>2011</b> , 12, 92-9		30
399	Challenges of ensuring adherence to oral therapy in patients with solid malignancies. <b>2011</b> , 8, 254-262		3



398	Compliance with the Protocol Considered Emetogenic Potential for Prophylaxis of Chemotherapy Induced Nausea and Vomiting. <b>2011</b> , 11, 58	
397	Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients. <b>2011</b> , 3, 151-60	9
396	A New Candidate Supporting Drug, Rikkunshito, for the QOL in Advanced Esophageal Cancer Patients with Chemotherapy Using Docetaxel/5-FU/CDDP. <b>2011</b> , 2011, 715623	17
395	Gastrointestinal Pharmacology. <b>2011</b> , 1234-1247	1
394	Summary of presentations from the 46th annual meeting of the American Society of Clinical Oncology (2010): focus on supportive care issues related to lung cancer. <b>2011</b> , 6, 645-9	1
393	[Induced nausea and vomiting induced by mFOLFOX6 and FOLFIRI with advanced colorectal cancer: a retrospective survey]. <b>2011</b> , 131, 1661-6	1
392	Guidelines for supportive care in multiple myeloma 2011. <b>2011</b> , 154, 76-103	138
391	Combined ifosfamide, etoposide and oxalipatin chemotherapy, a low-toxicity regimen for first-relapsed or refractory Hodgkin lymphoma after ABVD/EBVP: a prospective monocentre study on 34 patients. <b>2011</b> , 153, 191-8	18
390	Therapeutics of 5-HT3 receptor antagonists: current uses and future directions. <b>2011</b> , 130, 338-47	69
389	Supportive care for children with cancer. <b>2011</b> , 38, 374-9	12
388	Pharmacologic management of cancer-related pain, dyspnea, and nausea. <b>2011</b> , 38, 450-9	14
387	Palliative radiotherapy for bone metastases in the last 3 months of life: worthwhile or futile?. <b>2011</b> , 23, 709-15	31
386	Pemirolast reduces cisplatin-induced kaolin intake in rats. <b>2011</b> , 661, 57-62	15
385	Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics. <b>2011</b> , 33, 33-43	39
384	Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting. <b>2011</b> , 19, 131-40	80
383	Antiemetic activity of megestrol acetate in patients receiving chemotherapy. <b>2011</b> , 19, 667-73	5
382	Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. <b>2011</b> , 19, 807-13	84
381	Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. <b>2011</b> , 19, 823-32	67

380	Use of antiemetics in the management of chemotherapy-related nausea and vomiting in current UK practice. <b>2011</b> , 19, 949-56	15
379	Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy. <b>2011</b> , 19, 1159-64	30
378	Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009. <b>2011</b> , 19 Suppl 1, S5-14	70
377	Acute emesis: moderately emetogenic chemotherapy. <b>2011</b> , 19 Suppl 1, S15-23	18
376	Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL). <b>2011</b> , 19, 1505-10	18
375	Guidelines for the control of nausea and vomiting with chemotherapy of low or minimal emetic potential. <b>2011</b> , 19 Suppl 1, S33-6	10
374	Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009. <b>2011</b> , 19 Suppl 1, S37-42	39
373	Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only). <b>2011</b> , 19 Suppl 1, S57-62	25
372	Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists. <b>2011</b> , 19, 1983-90	36
371	Incidence of delayed nausea and vomiting in patients with colorectal cancer receiving irinotecan-based chemotherapy. <b>2011</b> , 19, 2063-6	8
370	Patient- and treatment-related risk factors for nausea and emesis during concurrent chemoradiotherapy. <b>2011</b> , 187, 1-6	15
369	[Side effects of tumor pharmacotherapy. What internists should know]. <b>2011</b> , 52, 1429-45; quiz 1446	3
368	Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer. <b>2011</b> , 67, 783-90	4
367	Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant. <b>2011</b> , 67, 1313-21	9
366	Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients. <b>2011</b> , 68, 653-9	32
365	Supportive Therapie in der gynkologischen Onkologie. <b>2011</b> , 44, 717-724	
364	Randomized, double-blind, crossover study of palonosetron compared with granisetron for the prevention of chemotherapy-induced nausea and vomiting in a Chinese population. <b>2011</b> , 28, 71-8	17
363	Palonosetron for prevention of acute and delayed nausea and vomiting in non-small-cell lung carcinoma patients. <b>2011</b> , 28, 1425-9	13

362	Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <b>2011</b> , 57, 191-8	58
361	Effect of brain stem and dorsal vagus complex dosimetry on nausea and vomiting in head and neck intensity-modulated radiation therapy. <b>2011</b> , 36, 41-5	19
360	[German S3-guideline "Diagnosis and treatment of esophagogastric cancer"]. <b>2011</b> , 49, 461-531	204
359	Prevention, diagnosis, therapy, and follow-up of lung cancer: interdisciplinary guideline of the German Respiratory Society and the German Cancer Society. <b>2011</b> , 65, 39-59	105
358	The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination. <b>2011</b> , 46, 784-9	23
357	[Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version]. <b>2011</b> , 65, e51-75	47
356	Effectively managing chemotherapy-induced nausea and vomiting. <b>2011</b> , 20, S7-8, S10-2, S14-15	9
355	Chemotherapy induced nausea and vomiting: a European perspective. <b>2011</b> , 20, S22, S25-8	5
354	Pharmacokinetics of oral dexamethasone and midazolam when administered with single-dose intravenous 150 mg fosaprepitant in healthy adult subjects. <b>2011</b> , 51, 1712-20	22
353	Antiemetics for chemotherapy-induced nausea and vomiting occurring despite prophylactic antiemetic therapy. <b>2011</b> , 14, 810-4	24
352	Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting. <b>2011</b> , 17, 179-85	11
351	Literature review and global consensus on management of acute radiation syndrome affecting nonhematopoietic organ systems. <b>2011</b> , 5, 183-201	54
350	Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy. <b>2011</b> , 41, 1168-76	21
349	Benzodiazepine use in breast cancer survivors: findings from a consecutive series of 1,000 patients. <b>2011</b> , 81, 9-11	10
348	CINV in the UK: a prospective audit of patient experience. <b>2011</b> , 20, S29-31	1
347	Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting. <b>2011</b> , 11, 481-8	12
346	A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adults. <b>2011</b> , 16, 207-16	43
345	Antiemetics: American Society of Clinical Oncology clinical practice guideline update. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 4189-98	2.2 606

- 344 Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. **2011**, 22, 939-946 29
- 343 Paclitaxel and Bevacizumab Regimen for Metastatic Breast Cancer. *Hospital Pharmacy*, **2011**, 46, 19-22 1.1
- 342 Prophylaxis and treatment of chemotherapy-induced nausea and vomiting. **2011**, 16-23
- 341 CODOX-M/IVAC for non-Hodgkin Lymphomas. *Hospital Pharmacy*, **2011**, 46, 91-100 1.1
- 340 Paclitaxel, Carboplatin, and Bevacizumab. *Hospital Pharmacy*, **2011**, 46, 406-414 1.1
- 339 Gemcitabine and Carboplatin (GC) Regimen for Advanced Non-Small-Cell Lung Cancer. *Hospital Pharmacy*, **2011**, 46, 322-326 1.1
- 338 Radiotherapy-induced nausea and vomiting. **2011**, 11, 685-92 19
- 337 Nausea and Vomiting. **2012**, 171-181
- 336 Palliative Care and Quality of Life. **2012**, 597-630.e6
- 335 Aprepitant (Emend) significantly increases sirolimus levels in patients undergoing allogeneic hematopoietic SCT. **2012**, 47, 291-3 10
- 334 Therapeutic case conference from Northwestern: an elderly gentleman with an unsteady gait. **2012**, 19, 199-203
- 333 [Supportive therapy in medical therapy of head and neck tumors]. **2012**, 91 Suppl 1, S151-75 2
- 332 Medroxyprogesterone acetate for refractory emesis in cisplatin-treated patients. **2012**, 15, 1158-60 1
- 331 First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours. **2012**, 106, 1379-85 16
- 330 Electroacupuncture for Nausea, Vomiting, and Myelosuppression in Women Receiving Adjuvant Chemotherapy for Early Breast Cancer: A Randomized Controlled Pilot Trial. **2012**, 24, 241-248 8
- 329 Prevalence of Delayed Nausea and/or Vomiting in Patients Treated With Oxaliplatin-Based Regimens for Colorectal Cancer. **2012**, 8, 136-40 5
- 328 Effectiveness of palonosetron versus other serotonin 5-HT<sub>3</sub> receptor antagonists in triple antiemetic regimens during multiday highly emetogenic chemotherapy. **2012**, 46, 1637-44 3
- 327 Prevention of delayed nausea: a University of Rochester Cancer Center Community Clinical Oncology Program study of patients receiving chemotherapy. *Journal of Clinical Oncology*, **2012**, 30, 3389-95 48

326	Optimal dose period for ondansetron tablets for preventing chemotherapy-induced nausea and vomiting with modified FOLFOX6: a randomized pilot study. <b>2012</b> , 58, 439-44	
325	Supportive care in hemato-oncology: a review in light of the latest guidelines. <i>Turkish Journal of Haematology</i> , <b>2012</b> , 29, 1-9	0.9
324	Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review. <b>2012</b> , 104, 1280-92	93
323	Adverse effects of dexamethasone and their management in patients with cutaneous T-cell lymphoma. <b>2012</b> , 16, E164-72	17
322	Drugs for the treatment of nausea and vomiting in adult patients in the emergency department setting. <b>2012</b> ,	3
321	Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting. <b>2012</b> , 10, 487-92	49
320	Impact of chemotherapy-induced nausea and vomiting on quality of life in Indonesian patients with gynecologic cancer. <b>2012</b> , 22, 139-45	17
319	The therapeutic potential of cannabis and cannabinoids. <b>2012</b> , 109, 495-501	176
318	Psychosocial issues. 823-838	1
317	Communicating about chemotherapy-induced nausea and vomiting: a comparison of patient and provider perspectives. <b>2012</b> , 10, 149-57	49
316	Antiemesis. <b>2012</b> , 10, 456-85	38
315	[Comparison of 1 mg/body and 3 mg/body of intravenous granisetron for the prevention of chemotherapy-induced nausea and vomiting and adverse events in hematological malignancy patients]. <b>2012</b> , 132, 675-81	1
314	Highly cited German research contributions to the fields of radiation oncology, biology, and physics: focus on collaboration and diversity. <b>2012</b> , 188, 865-72	4
313	Degree of freezing does not affect efficacy of frozen gloves for prevention of docetaxel-induced nail toxicity in breast cancer patients. <b>2012</b> , 20, 2017-24	14
312	Using aprepitant as secondary antiemetic prophylaxis for cancer patients with cisplatin-induced emesis. <b>2012</b> , 20, 2357-61	12
311	Pharmaceutical care for patients with breast and ovarian cancer. <b>2012</b> , 20, 2669-77	23
310	Identification of a novel marker associated with risk for delayed chemotherapy-induced vomiting. <b>2012</b> , 20, 2803-9	5
309	Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients' quality of life. <b>2012</b> , 20, 3141-8	92

308	A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancer. <b>2012</b> , 136, 143-51		6
307	Prophylaxis of radiation-induced nausea and vomiting using 5-hydroxytryptamine-3 serotonin receptor antagonists: a systematic review of randomized trials. <b>2012</b> , 82, 408-17		42
306	Design of experiments as a tool for LC-MS/MS method development for the trace analysis of the potentially genotoxic 4-dimethylaminopyridine impurity in glucocorticoids. <b>2012</b> , 70, 251-8		43
305	[Comparative study of the efficacy and safety of two anti-emetic protocols in gynecological chemotherapy]. <b>2012</b> , 36, 220-8		
304	Emergencies in Pediatric Oncology. <b>2012</b> ,		1
303	Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimen: a hoosier oncology group study. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3998-1003	2.2	75
302	Approach to the Patient with Cancer. <b>2012</b> , 1164-1177		1
301	An Overview of Acupuncture and Moxibustion for Cancer Care. <b>2012</b> , 1-18		3
300	Treatment of chemotherapy-induced nausea. <b>2012</b> , 9, 20-26		24
299	Antiemetic control with palonosetron in patients with gastrointestinal cancer receiving a fluoropyrimidine-based regimen in addition to either irinotecan or oxaliplatin: a retrospective study. <b>2012</b> , 83, 135-40		1
298	Overview of supportive care in patients receiving chemotherapy: antiemetics, pain management, anemia, and neutropenia. <b>2012</b> , 25, 209-221		8
297	Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trial. <b>2012</b> , 12, 603		12
296	Use of transdermal and intravenous granisetron and the ability of the Hesketh score to assess nausea and vomiting induced by multiday chemotherapy. <i>Cancer Management and Research</i> , <b>2012</b> , 4, 171-6	3.6	2
295	Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting. <b>2012</b> , 19, e414-21		37
294	Antiemetic Use in Oncology: Updated Guideline Recommendations from ASCO. <b>2012</b> , 532-40		18
293	Caplri (Xellri) Regimen for Advanced and Metastatic Colorectal or Esophogastric Cancer. <i>Hospital Pharmacy</i> , <b>2012</b> , 47, 98-105	1.1	
292	Efficacy and cost: avoiding undertreatment of chemotherapy-induced nausea and vomiting. <b>2012</b> , 16, E133-41		19
291	Assessment of the relationship between adherence with antiemetic drug therapy and control of nausea and vomiting in breast cancer patients receiving anthracycline-based chemotherapy. <b>2012</b> , 18, 385-94		30

290	Antiemetische Prophylaxe und Therapie bei chemo- und radiotherapieinduzierter Nausea und Emesis. <b>2012</b> , 7, 38-51	
289	The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients. <b>2012</b> , 69, 1189-96	14
288	Transient elevation of serum cystatin C concentrations during perioperative cisplatin-based chemotherapy in esophageal cancer patients. <b>2012</b> , 69, 1537-44	13
287	Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy. <b>2012</b> , 20, 1043-7	17
286	Comparative trial of two intravenous doses of granisetron (1 versus 3 mg) in the prevention of chemotherapy-induced acute emesis: a double-blind, randomized, non-inferiority trial. <b>2012</b> , 20, 1057-64	10
285	Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study. <b>2012</b> , 20, 1471-8	24
284	A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy. <b>2012</b> , 20, 1507-14	24
283	A pilot study of adrenal suppression after dexamethasone therapy as an antiemetic in cancer patients. <b>2012</b> , 20, 1565-72	16
282	Prophylaxis of radiotherapy-induced nausea and vomiting in the palliative treatment of bone metastases. <b>2012</b> , 20, 1673-8	20
281	Implementation of institutional antiemetic guidelines for low emetic risk chemotherapy with docetaxel: a clinical and cost evaluation. <b>2012</b> , 20, 1805-10	5
280	Mise à jour des recommandations de la MASCC et de l'ESMO pour la prévention des nausées et vomissements chimio- et radio-induits: résultats de la conférence de consensus de P'ouse. <b>2012</b> , 14, 329-342	3
279	Predicting the emetic liability of novel chemical entities: a comparative study. <b>2012</b> , 165, 1848-1867	38
278	The intersection between cannabis and cancer in the United States. <b>2012</b> , 83, 1-10	45
277	Development of fast dissolving oral film containing dexamethasone as an antiemetic medication: clinical usefulness. <b>2012</b> , 424, 12-7	25
276	Pharmacists contribute to the improved efficiency of medical practices in the outpatient cancer chemotherapy clinic. <b>2012</b> , 18, 753-60	33
275	Use of high-dose cisplatin with aprepitant in an outpatient setting. <b>2012</b> , 21, 436-41	11
274	Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonist. <b>2012</b> , 30, 662-71	5
273	Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. <b>2012</b> , 20, 107-17	120

272	Factors associated with weight loss during radiotherapy in patients with stage I or II head and neck cancer. <b>2012</b> , 20, 591-9	26
271	Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy. <b>2012</b> , 20, 615-23	14
270	Phase II study of weekly PM00104 (ZALYPSIS(®)) in patients with pretreated advanced/metastatic endometrial or cervical cancer. <b>2013</b> , 30, 627	14
269	Compatibility of intravenous fosaprepitant with intravenous 5-HT3 antagonists and corticosteroids. <b>2013</b> , 72, 509-13	7
268	A phase I pharmacokinetic study of PM00104 (Zalypsis) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors. <b>2013</b> , 71, 1247-54	8
267	A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy. <b>2013</b> , 109, 859-65	51
266	Prevention of Nausea and Vomiting in Cancer Patients. <b>2013</b> ,	
265	Pharmacology of Postoperative Nausea and Vomiting. <b>2013</b> , 503-522	2
264	Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens. <b>2013</b> , 19, 49-55.e1	48
263	Effets indésirables des médicaments anticancéreux utilisés en pneumologie. <b>2013</b> , 5, 367-374	
262	Phase-I study of sagopilone in combination with cisplatin in chemotherapy-naïve patients with metastasised small-cell lung cancer. <b>2013</b> , 49, 2461-8	5
261	The interaction of ifosfamide and aprepitant in gynecologic malignancies. <b>2013</b> , 6, 34-5	8
260	Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer. <b>2013</b> , 22, 142-149	10
259	Management of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents. <b>2013</b> , 73, 249-62	120
258	Leukaemia update. Part 2: managing patients with leukaemia in the community. <b>2013</b> , 346, f1932	2
257	Special Care of Blood and Marrow Stem Transplant Patients. <b>2013</b> , 1321-1345	
256	Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis. <b>2013</b> , 104, 711-7	94
255	Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. <b>2013</b> , 60, 1073-82	90



254	Review of the efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in a range of tumor types. <b>2013</b> , 39, 113-7		22
253	Postsurgical screening for psychosocial disorders in neurooncological patients. <b>2013</b> , 155, 2255-61		18
252	Association of ABCB1 polymorphisms with the antiemetic efficacy of granisetron plus dexamethasone in breast cancer patients. <b>2013</b> , 28, 299-304		21
251	Comparison of emetic potencies of the 8-ketotrichothecenes deoxynivalenol, 15-acetyldeoxynivalenol, 3-acetyldeoxynivalenol, fusarenon X, and nivalenol. <b>2013</b> , 131, 279-91		37
250	Using a simple diary for management of nausea and vomiting during chemotherapy. <b>2013</b> , 17, 479-81		2
249	Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. <b>2013</b> , 24, 1067-73		81
248	A retrospective review of antiemetic use for chemotherapy-induced nausea and vomiting in pediatric oncology patients at a tertiary care center. <b>2013</b> , 19, 138-44		4
247	Modified FOLFOX6 chemotherapy in patients with metastatic urachal cancer. <b>2013</b> , 59, 402-6		29
246	Feasibility and acceptance of a pharmacist-run tele-oncology service for chemotherapy-induced nausea and vomiting in ambulatory cancer patients. <b>2013</b> , 19, 387-95		19
245	WITHDRAWN: Serotonin receptor antagonists for highly emetogenic chemotherapy in adults. <i>The Cochrane Library</i> , <b>2013</b> , CD006272	5.2	2
244	Prevention of chemotherapy-induced nausea and vomiting and the role of neurokinin 1 inhibitors: from guidelines to clinical practice in solid tumors. <b>2013</b> , 24, 99-111		13
243	Effect of dexamethasone on extracellular secretion of cystatin C in cancer cell lines. <b>2013</b> , 1, 115-118		9
242	Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: a retrospective evaluation. <b>2013</b> , 29, 1285-92		113
241	[Results and lessons of an innovating chemotherapy-induced nausea and vomiting management strategy]. <i>Bulletin Du Cancer</i> , <b>2013</b> , 100, 799-810	2.4	1
240	The safety of chemotherapy for breast cancer patients with hepatitis C virus infection. <b>2013</b> , 4, 519-23		12
239	Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK. <i>Cancer Management and Research</i> , <b>2013</b> , 5, 215-24	3.6	21
238	How Should Medications Be Initiated and Titrated to Reduce Acute and Delayed Nausea and Vomiting in the Setting of Chemotherapy?. <b>2013</b> , 135-140		
237	Influences of Stress, Anxiety, Depression, and Personality Trait on Nausea, Vomiting, and Retching of Breast Cancer Patients Receiving Chemotherapy. <b>2013</b> , 52, 327		

236	Clinical practice guidelines and consensus statements in oncology--an assessment of their methodological quality. <b>2014</b> , 9, e110469	20
235	Pharmacovigilance in oncology: pattern of spontaneous notifications, incidence of adverse drug reactions and under-reporting. <b>2014</b> , 50, 411-422	2
234	Nausea and Vomiting in Cancer Patients: Topic Review. <b>2014</b> , 05,	1
233	Medical marijuana: A panacea or scourge. <b>2014</b> , 31, 145-8	3
232	Plant and Marine Sources. <b>2014</b> , 43-113	1
231	Economic analysis of aprepitant-containing regimen to prevent chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Hong Kong. <b>2014</b> , 10, 80-91	14
230	Development and testing of the patient-reported chemotherapy indicators of symptoms and experience: patient-reported outcome and process indicators sensitive to the quality of nursing care in ambulatory chemotherapy settings. <b>2014</b> , 37, E52-60	7
229	Aprepitant reduces chemotherapy-induced vomiting in children and young adults with brain tumors. <b>2014</b> , 31, 277-83	5
228	Evaluating the various phases of cisplatin-induced emesis in rats. <b>2014</b> , 8, 2017-2022	7
227	Palonosetron exhibits higher total control rate compared to first-generation serotonin antagonists and improves appetite in delayed-phase chemotherapy-induced nausea and vomiting. <b>2014</b> , 2, 375-379	3
226	The effectiveness of acupressure for the control and management of chemotherapy-related acute and delayed nausea: a randomized controlled trial. <b>2014</b> , 47, 12-25	32
225	Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). <b>2014</b> , 140, 319-28	132
224	Prescription trends of prophylactic antiemetics for chemotherapy-induced nausea and vomiting in Japan. <b>2014</b> , 22, 1789-95	3
223	Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer. <b>2014</b> , 32, 123-34	4
222	Influence of pharmaceutical care on the delayed emesis associated with chemotherapy. <b>2014</b> , 36, 287-90	13
221	An approach to chemotherapy-associated toxicity. <b>2014</b> , 32, 167-203	66
220	Efficacy of a triple antiemetic regimen with aprepitant for the prevention of chemotherapy-induced nausea and vomiting: effects of gender, age, and region. <b>2014</b> , 30, 1875-81	11
219	Psychopharmacology in Oncology and Palliative Care. <b>2014</b> ,	4

218	International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. <b>2014</b> , 722, 197-202		116
217	First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors. <b>2014</b> , 20, 2205-14		54
216	Safety and efficacy of aprepitant for chemotherapy-induced nausea and vomiting in pediatric patients: a prospective, observational study. <b>2014</b> , 61, 1111-3		13
215	Is newer safer? Adverse events associated with first-line therapies for ANCA-associated vasculitis and lupus nephritis. <b>2014</b> , 9, 1657-67		23
214	Nausea and Vomiting. <b>2015</b> , 49-60		
213	Profile Analysis of Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study. <b>2015</b> , 55, 749-55		5
212	QoL evaluation of olanzapine for chemotherapy-induced nausea and vomiting comparing with 5-HT3 receptor antagonist. <b>2015</b> , 24, 436-43		17
211	Drugs for the treatment of nausea and vomiting in adults in the emergency department setting. <i>The Cochrane Library</i> , <b>2015</b> , CD010106	5.2	14
210	. <b>2015</b> ,		4
209	The impact of 5-hydroxytryptamine-receptor antagonists on chemotherapy treatment adherence, treatment delay, and nausea and vomiting. <i>Cancer Management and Research</i> , <b>2015</b> , 7, 175-88	3.6	8
208	Efficacy and Safety of Aprepitant and Dexamethasone in the Prevention of Nausea and Vomiting from Neoadjuvant or Adjuvant Anthracyclines and Cyclophosphamide Combination Therapy in Patients with Breast Cancer. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , <b>2015</b> , 41, 603-611	0.1	2
207	Prophylactic Management of Radiation-Induced Nausea and Vomiting. <b>2015</b> , 2015, 893013		14
206	Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. <b>2015</b> , 26, 1081-1090		110
205	Glucocorticoid Signaling. <b>2015</b> ,		8
204	Glucocorticoids and Cancer. <b>2015</b> , 872, 315-33		97
203	Addition of Aprepitant (Emend <sup>®</sup> ) to Standard Antiemetic Regimen Continued for 7 Days after Chemotherapy for Stem Cell Transplantation Provides Significant Reduction of Vomiting. <b>2015</b> , 89, 31-6		12
202	5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy. <b>2015</b> , 1848, 2738-46		26
201	Cohort study of consistency between the compliance with guidelines for chemotherapy-induced nausea and vomiting and patient outcome. <b>2015</b> , 16, 5		7

200	Adherence to antiemetic guidelines and control of chemotherapy-induced nausea and vomiting (CINV) in a large hospital. <b>2015</b> , 21, 163-9		15
199	Bioequivalence of ondansetron oral soluble film 8 mg (ZUPLENZ) and ondansetron orally disintegrating tablets 8 mg (ZOFRAN) in healthy adults. <b>2015</b> , 22, 90-7		14
198	Improved anti-emetic efficacy of 5-HT3 receptor antagonists in cancer patients with genetic polymorphisms of ABCB1 (MDR1) drug transporter. <b>2015</b> , 116, 354-60		14
197	Can administrative data be used to measure chemotherapy side effects?. <b>2015</b> , 15, 215-22		3
196	Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study. <b>2015</b> , 23, 2833-40		40
195	Infections in Hematology. <b>2015</b> ,		5
194	DRUG UTILIZATION EVALUATION AND COST ANALYSIS OF ANTIEMETIC DRUGS PRESCRIBED IN ONCOLOGY WARD IN A QUATERNARY CARE HOSPITAL. <b>2016</b> , 9, 97		
193	Carboplatin and Liposomal Doxorubicin for Ovarian Cancer. <i>Hospital Pharmacy</i> , <b>2016</b> , 51, 442-9	1.1	4
192	The Efficacy, Safety, and Cost Benefit of Olanzapine versus Aprepitant in Highly Emetogenic Chemotherapy: A Pilot Study from South India. <b>2016</b> , 2016, 3439707		24
191	Management del paziente con diarrea, nausea e vomito, malnutrizione e malattia celiaca: lo stato dell'arte. <b>2016</b> , 4, 1		1
190	Changes in blood concentrations of trace metals in cancer patients receiving cisplatin-based chemotherapy. <b>2016</b> , 5, 737-744		8
189	Ovarian cancer: avoiding compromising quality of life during intense chemotherapy sessions. <b>2016</b> , 1, 277-288		
188	A phase II, randomized study of aprepitant in the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapies in colorectal cancer patients. <b>2016</b> , 4, 393-398		12
187	Phase II randomized, controlled trial of 1 day versus 3 days of dexamethasone combined with palonosetron and aprepitant to prevent nausea and vomiting in Japanese breast cancer patients receiving anthracycline-based chemotherapy. <b>2016</b> , 24, 1405-11		11
186	Examining racial variation in antiemetic use and post-chemotherapy health care utilization for nausea and vomiting among breast cancer patients. <b>2016</b> , 24, 4839-4847		7
185	An Analysis of Behavioral and Genetic Risk Factors for Chemotherapy-Induced Nausea and Vomiting in Japanese Subjects. <b>2016</b> , 39, 1852-1858		8
184	Total Body Irradiation. <b>2016</b> , 341-357.e7		1
183	Efficacy analysis of the aprepitant-combined antiemetic prophylaxis for non-round cell soft-tissue sarcoma patients received adriamycin and ifosfamide therapy. <b>2016</b> , 95, e5460		2

182	Antiemetics: American Society of Clinical Oncology Focused Guideline Update. <b>2016</b> , 12, 88-89		3
181	Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: A systematic review. <b>2016</b> , 99, 13-36		72
180	Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin. <b>2016</b> , 21, 491-7		50
179	Medical Marijuana Use in Oncology: A Review. <b>2016</b> , 2, 670-675		60
178	Controlled transdermal iontophoresis for poly-pharmacotherapy: Simultaneous delivery of granisetron, metoclopramide and dexamethasone sodium phosphate in vitro and in vivo. <b>2016</b> , 85, 31-8		24
177	Supportive Cancer Care. <b>2016</b> ,		
176	Management of Chemotherapy-Induced Nausea and Vomiting. <b>2016</b> ,		3
175	Investigating racial disparities in use of NK1 receptor antagonists to prevent chemotherapy-induced nausea and vomiting among women with breast cancer. <b>2016</b> , 156, 351-9		10
174	Antiemetics: American Society of Clinical Oncology Focused Guideline Update. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 381-6	2.2	150
173	Poor chemotherapy-induced nausea and vomiting control in children receiving intermediate or high dose methotrexate. <b>2016</b> , 24, 1365-71		9
172	Electroacupuncture alleviates cisplatin-induced nausea in rats. <b>2016</b> , 34, 120-6		14
171	Neuromotor tolerability and behavioural characterisation of cannabidiolic acid, a phytocannabinoid with therapeutic potential for anticipatory nausea. <b>2016</b> , 233, 243-54		17
170	Emetic responses to T-2 toxin, HT-2 toxin and emetine correspond to plasma elevations of peptide YY3-36 and 5-hydroxytryptamine. <b>2016</b> , 90, 997-1007		23
169	Effects of chemotherapy on the health-related quality of life of Japanese lower rectal cancer patients after sphincter-saving surgery. <b>2017</b> , 35, 468-482		2
168	Pharmacology of Antiemetics: Update and Current Considerations in Anesthesia Practice. <b>2017</b> , 35, e41-e54		6
167	A phase II randomized double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumor patients receiving moderately to highly emetogenic chemotherapy. <b>2017</b> , 34, 69		34
166	Synthetic and natural antioxidants attenuate cisplatin-induced vomiting. <b>2017</b> , 18, 4		15
165	Effectiveness of aprepitant in addition to ondansetron in the prevention of nausea and vomiting caused by fractionated radiotherapy to the upper abdomen (AVERT). <b>2017</b> , 25, 1503-1510		2

164	A phase II randomised study to evaluate the efficacy of aprepitant plus palonosetron for preventing delayed-phase CINV associated with TC therapy in gynaecological cancer. <b>2017</b> , 43, 1454-1459		4
163	Comparative investigation of the anti-emetic effects of granisetron and palonosetron during the treatment of acute myeloid leukemia. <b>2017</b> , 7, 629-632		2
162	Longitudinal perceptions of the side effects of chemotherapy in patients with gynecological cancer. <b>2017</b> , 25, 3457-3464		21
161	NCCN Guidelines Insights: Antiemesis, Version 2.2017. <b>2017</b> , 15, 883-893		92
160	2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents. <b>2017</b> , 25, 271-275		18
159	Moxibustion for Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Meta-Analysis. <b>2017</b> , 2017, 9854893		14
158	Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3240-3261	2.2	351
157	Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update Summary. <b>2017</b> , 13, 825-830		15
156	Combination of Aprepitant, Azasetron, and Dexamethasone as Antiemetic Prophylaxis in Women with Gynecologic Cancers Receiving Paclitaxel/Carboplatin Therapy. <b>2017</b> , 23, 826-833		2
155	A prospective cohort study of patient-reported vomiting, retching, nausea and antiemetic use during neoadjuvant long-course radiation therapy and concurrent 5-fluorouracil-based chemotherapy for rectal adenocarcinoma. <b>2018</b> , 10, 42-46		1
154	Direct modification of the 5-HT receptor current by some anticancer drugs. <b>2018</b> , 821, 21-28		3
153	Palliative Care and Quality of Life. <b>2018</b> , 528-559.e7		0
152	A randomized placebo-controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization. <b>2018</b> , 67, 575-585		32
151	Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06). <b>2018</b> , 21, 421-427		18
150	A Comparative Safety Profile Assessment of Oncolytic Virus Therapy Based on Clinical Trials. <b>2018</b> , 52, 430-437		12
149	Prevention of post-embolization syndrome after transarterial chemoembolization for hepatocellular carcinoma-is prophylactic dexamethasone useful, or not?. <b>2018</b> , 7, 214-216		5
148	Correspondence. <b>2018</b> , 68, 1207-1208		
147	Nausea and Vomiting. <b>2018</b> , 391-408		

146	[Extrapyramidal adverse reactions to metoclopramide. A pharmacovigilance survey]. <b>2018</b> , 146, 876-884	
145	Efficacy and Safety of Aprepitant in Combination with Dexamethasone, Granisetron and Metoclopramide as a Prophylaxis of Chemotherapy-Induced Nausea and Vomiting in a Acute and Delayed Emesis in Arab Cancer Patient. <b>2018</b> , 02,	
144	Analysis of adverse events of renal impairment related to platinum-based compounds using the Japanese Adverse Drug Event Report database. <b>2018</b> , 6, 2050312118772475	6
143	Reduction in nephrotoxicities using short hydration for chemotherapy containing cisplatin: a consecutive analysis of 467 patients with thoracic malignancies. <b>2018</b> , 3, e000342	5
142	Analysis of Dietary Intake during Consecutive-Day Chemotherapy for Bone and Soft-Tissue Sarcomas. <b>2017</b> , 4, 70	2
141	A retrospective review of treatment patterns of antiemetic agents for chemotherapy-induced nausea and vomiting. <b>2018</b> , 6, 2050312118767234	1
140	A unique schedule of palonosetron, ondansetron, and dexamethasone for the prevention of delayed nausea and vomiting in patients receiving myeloablative chemotherapy. <b>2019</b> , 25, 1336-1342	
139	Impact of adjuvant lorazepam with granisetron on chemotherapy-induced nausea and vomiting in pediatric patients with acute lymphoblastic leukemia. <b>2019</b> , 27, 895-899	4
138	Latest Update on Prevention of Acute Chemotherapy-Induced Nausea and Vomiting in Pediatric Cancer Patients. <b>2019</b> , 21, 89	8
137	Analysis of concordance with antiemetic guidelines in pediatric, adolescent, and young adult patients with cancer using a large-scale administrative database. <b>2019</b> , 8, 6243-6249	2
136	Modulation of the 5-HTA receptor current by desacylbaldrinol. <b>2021</b> , 35, 2758-2762	1
135	Budget impact of netupitant/palonosetron for the prevention of chemotherapy-induced nausea and vomiting. <b>2019</b> , 22, 840-847	2
134	Relative bioavailability of an extemporaneously prepared aprepitant oral suspension in healthy adults. <b>2019</b> , 25, 1907-1915	2
133	S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial. <b>2019</b> , 51, 1-11	13
132	Cisplatin: The first metal based anticancer drug. <b>2019</b> , 88, 102925	368
131	Nonpain Symptom Management. <b>2019</b> , 46, 335-351	
130	Pharmacology of Postoperative Nausea and Vomiting. <b>2019</b> , 671-692	6
129	First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors. <b>2019</b> , 37, 674-683	11

128	Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type. <b>2020</b> , 20, 918		0
127	Granisetron transdermal system and dexamethasone for the prevention of nausea and vomiting in multiple myeloma patients receiving chemo-mobilization: An observational real-world study of effectiveness and safety. <b>2020</b> , 59, 102911		
126	Upregulation of the long noncoding RNAs DSCAM-AS1 and MANCR is a potential diagnostic marker for breast carcinoma. <b>2020</b> ,		6
125	Antiemetics: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 2782-2797	2.2	63
124	Dexamethasone prevents TACE-induced adverse events: A meta-analysis. <b>2020</b> , 99, e23191		2
123	Pharmacokinetics and Safety of Fosaprepitant Dimeglumine in Healthy Chinese Volunteers: Bioequivalence Study. <b>2021</b> , 10, 748-755		1
122	Antiemetic prophylaxis in patients undergoing hematopoietic stem cell transplantation: a multicenter survey of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) transplant programs. <b>2020</b> , 99, 867-875		4
121	Guideline concordant care for prevention of acute chemotherapy-induced nausea and vomiting in children, adolescents, and young adults. <b>2020</b> , 28, 4761-4769		8
120	BIOAVAILABILITY STUDY OF ONDANSETRON GEL IN RABBITS AND HUMAN VOLUNTEERS APPLYING UPLC AS ANALYTICAL TOOL AND EVALUATION OF THE ANTIEMETIC EFFECT OF ONDANSETRON GEL IN CISPLATIN-INDUCED EMESIS IN RATS. <b>2020</b> , 68-82		
119	Chemotherapy-Induced Nausea and Vomiting.		1
118	The Ferret in Nausea and Vomiting Research: Lessons in Translation of Basic Science to the Clinic. 735-778		6
117	Multiparticulate Technologies for Fixed-Dose Combinations. <b>2017</b> , 155-168		1
116	Chemotherapy-Induced Nausea and Vomiting: Molecular Mechanisms and Clinical Approaches. <b>2015</b> , 779-804		1
115	Folate Antagonists. <b>2011</b> , 125-143		1
114	Nausea, Vomiting, and Early Satiety. <b>2009</b> , 921-931		1
113	Anesthesia and Treatment of Chronic Pain. <b>2010</b> , 1797-1818		4
112	NEUROTRANSMITTERS. <b>2009</b> , 91-113		2
111	Total Body Irradiation. <b>2010</b> , 279-302		1



110	Nanotechnology based blended chitosan-pectin hybrid for safe and efficient consolidative antiemetic and neuro-protective effect of meclizine hydrochloride in chemotherapy induced emesis. <b>2020</b> , 584, 119411		18
109	Prospective validation of a prediction tool for identifying patients at high risk for chemotherapy-induced nausea and vomiting. <b>2013</b> , 11, 14-21		22
108	Use of neurokinin-1 receptor antagonists in patients receiving moderately or highly emetogenic chemotherapy. <b>2010</b> , 14, 500-4		4
107	Doxorubicin and Cisplatin Regimen for High-Grade Osteosarcoma or Malignant Fibrous Histiocytoma (MFH) of the Bone. <i>Hospital Pharmacy</i> , <b>2007</b> , 42, 605-610	1.1	1
106	[Prophylaxis of chemotherapy-induced vomiting and nausea]. <b>2008</b> , 52, 391-4		2
105	[Treatment of tumor therapy-induced nausea and vomiting]. <b>2009</b> , 53, 39-45		0
104	Influence of aprepitant and localization of the patch on fentanyl exposure in patients with cancer using transdermal fentanyl. <b>2018</b> , 9, 18269-18276		4
103	Chemotherapy-and cancer-related nausea and vomiting. <b>2008</b> , 15, S4-9		31
102	[American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer]. <b>2010</b> , 13, 171-89		6
101	Efficacy according to Dexamethasone Dose in Combination with Aprepitant and Granisetron during Cisplatin-based Chemotherapy. <b>2010</b> , 46, 88		1
100	Ramosetron hydrochloride for the prevention of cancer chemotherapy induced nausea and vomiting: The Indian experience. <b>2014</b> , 3, 132-7		4
99	Controlling Chemotherapy-Induced Nausea and Vomiting with Neurokinin-1 Receptor Antagonists in Patients on AC-Based Chemotherapy—Are We There Yet?. <b>2012</b> , 03, 90-102		1
98	Evaluation of Adherence to Chemotherapy-Induced Nausea and Vomiting Guidelines. An Observational Study. <b>2012</b> , 03, 613-620		6
97	Studies Regarding Quality Enhancement of Affairs by Pharmacist and Clinical Evaluation of Cancer Chemotherapy. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , <b>2015</b> , 41, 289-310	0.1	1
96	Efficacy of aprepitant in patients with advanced or recurrent lung cancer receiving moderately emetogenic chemotherapy. <b>2012</b> , 13, 4187-90		9
95	Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Patients. <b>2015</b> , 16, 6207-13		17
94	Doxorubicin and Docetaxel (AT/AD) for Breast Cancer. <i>Hospital Pharmacy</i> , <b>2006</b> , 41, 832-843	1.1	
93	Efficacy and Safety of Low Dose Steroids for Delayed Nausea Due to Anticancer Agents. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , <b>2007</b> , 33, 310-317	0.1	

- 92 Paclitaxel and Gemcitabine (PG) for Advanced Breast Cancer. *Hospital Pharmacy*, **2007**, 42, 510-516 1.1
- 91 Cancer Pain and Symptom Management: Drug Therapy. **2008**, 435-447
- 90 Chemotherapy-Induced Nausea and Vomiting. **2008**, 4, 19-23 4
- 89 Current Situation of Prophylaxis for Chemotherapy-induced Acute Emesis at Niigata Cancer Center Hospital. *Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)*, **2008**, 34, 781-787<sup>0.1</sup> 2
- 88 Usefulness of Cancer Chemotherapy Adverse Effects Manual in Department of Urology, Okayama University Hospital. *Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)*, **2008**, 34, 962-971 0.1
- 87 Palonosetron. **2008**, 29,
- 86 Vincristine, Doxorubicin, and Cyclophosphamide Alternating with Ifosfamide and Etoposide Regimen for Ewing's Sarcoma and Primitive Neuroectodermal Tumor (PNET) of Bone. *Hospital Pharmacy*, **2008**, 43, 367-372 1.1
- 85 [Experience with aprepitant in the prevention of nausea and vomiting caused by highly emetic chemotherapy of lung cancer]. **2008**, 52, 179-83
- 84 Docetaxel and Cyclophosphamide Regimen in the Treatment of Breast Cancer. *Hospital Pharmacy*, **2008**, 43, 710-714 1.1
- 83 Prérequis avant la mise en route d'une chimiothérapie pour cancer colorectal. **2009**, 30-46
- 82 Complications of Chemotherapy. **2009**, 1353-1360
- 81 Supportivtherapie bei Emesis. **2009**, 71-75
- 80 Updated Oncology Nursing Society putting evidence into practice resources. **2009**, 13, 137-43 2
- 79 Randomized, Double-blind, Placebo-controlled Trial on Preventive Effect of Cloxazolam against Cisplatin-induced Nausea and Vomiting. *Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)*, **2009**, 35, 316-324 0.1
- 78 Evaluation of Antiemetic Therapy for Prevention of Nausea and Vomiting Induced by Daily Administration of Anticancer Drugs. *Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)*, **2009**, 35, 609-614 0.1 2
- 77 Epirubicin, Cisplatin, and Fluorouracil (ECF) Regimen. *Hospital Pharmacy*, **2009**, 44, 1072-1081 1.1
- 76 Palonosetron for the prevention of chemotherapy-induced nausea and vomiting: approval and efficacy. *Cancer Management and Research*, **2009**, 1, 167-76 3.6 6
- 75 Nausea and Vomiting. **2010**, 231-239

74 Supportivtherapie bei Emesis. **2010**, 89-93

73 Effectiveness of Revised Antiemetic Therapy on Nausea and Vomiting Incidence and Cost of Antiemesis in Continuous Administration of Anticancer Drugs. *Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)*, **2010**, 36, 413-418 0.1

72 Evaluation of Alternate-day Administration of Dexamethasone for Prevention of Nausea, Vomiting and Anorexia Induced by Daily Administration of Ifosfamide. *Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)*, **2010**, 36, 542-548 0.1

71 Selection and Placement of Intraperitoneal Catheters for IP Chemotherapy for Ovarian Cancer. **2010**, 59-76

70 Gastrointestinal Tract. **2010**, 353-377

69 Supportive Care in Paediatric Oncology. **2010**, 49-62

68 Efficacy of Olanzapine against Nausea and Vomiting in Cancer Patients Receiving Chemotherapy. *Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)*, **2010**, 36, 717-722 0.1

67 Liposomal Doxorubicin and Bortezomib for Relapsed or Refractory Multiple Myeloma. *Hospital Pharmacy*, **2010**, 45, 201-223 1.1

66 The Review of Chemotherapy in Colorectal Cancer. *Journal of Korean Society of Health-System Pharmacists*, **2010**, 27, 139-151 0

65 Management of Nausea and Vomiting in Cancer Patients. **2011**, 453-471

64 Prophylactic antiemetics therapy against gynecologic cancer chemotherapy. *Korean Journal of Obstetrics & Gynecology*, **2011**, 54, 127

63 Belkeit und Erbrechen. **2011**, 393-415

62 Traitement symptomatique. **2011**, 210-301

61 Part Introduction. 33-280

60 An Overview of Gastrointestinal Side Effects in Tumour Therapy. **2011**, 257-267

59 Adults Receiving Chemotherapeutic Regimens. 158-183

58 Leucovorin, Fluorouracil, and Irinotecan (FOLFIRI) plus Bevacizumab for Metastatic Colorectal Cancer. *Hospital Pharmacy*, **2011**, 46, 748-754 1.1 1

57 Supportive Care. **2012**, 121-141

56	Need for pharmaceutical care during chemotherapy for prevention of side effects: examples of blood sugar monitoring in dexamethasone treatment. <i>Palliative Care Research</i> , <b>2012</b> , 7, 101-111	0.1	
55	Antiemetic effect of granisetron NK, a generic 5-HT <sub>3</sub> receptor antagonist in comparison with azasetron for prevention of chemotherapy-induced nausea and vomiting in cancer patient - A crossover randomized controlled clinical trial -. <i>Annals of Cancer Research and Therapy</i> , <b>2012</b> , 20, 63-67	0.2	1
54	Aprepitant Antiemetic Effect of Carboplatin-based Chemotherapy in Lung Cancer. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , <b>2012</b> , 38, 196-203	0.1	1
53	Total Body Irradiation. <b>2012</b> , 345-360		0
52	Neurokinin-1 receptor antagonists for prevention of chemotherapy-related nausea and vomiting in adults.		
51	Antiemetic Drugs. <b>2013</b> , 23-35		
50	Risk Factors Associated with Nausea and Vomiting After Radiotherapy. <b>2013</b> , 21-22		
49	Risk Factors Associated with Nausea and Vomiting After Chemotherapy. <b>2013</b> , 15-20		
48	Palliative Care for Cancer Patients and their Families. 401-418		
47	Antiemetic Prophylaxis of Radiotherapy-Induced Nausea and Vomiting. <b>2013</b> , 45-53		
46	Survey of the Efficacy and Cost of Administering Aprepitant to Non-small Cell Lung Cancer Patients Treated with Combination Therapy of Carboplatin and Paclitaxel Every 3 Weeks. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , <b>2013</b> , 39, 294-303	0.1	1
45	Evaluation of Aprepitant as Prophylactic Antiemetics of Highly Emetogenic Chemotherapy. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , <b>2013</b> , 39, 245-250	0.1	
44	Antiemetic Prophylaxis of Chemotherapy-Induced Nausea and Vomiting. <b>2013</b> , 37-43		
43	Nebenwirkungen und Supportivtherapie. <b>2014</b> , 179-208		
42	Anticipatory Nausea among Ambulatory Cancer Patients Receiving Chemotherapy: Associated with Beginning-of-using before and after the New Antiemetic Drugs. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , <b>2014</b> , 40, 165-173	0.1	
41	A Pharmacocybernetics Approach to Patient Safety. <i>Advances in Healthcare Information Systems and Administration Book Series</i> , <b>2014</b> , 179-197	0.3	
40	Nausea and Vomiting. <b>2014</b> , 626-634.e2		0
39	Psychopharmacology in Palliative Care and Oncology: Childhood and Adolescence. <b>2014</b> , 331-348		

- 38 Gastrointestinal Complications. **2015**, 197-210
- 37 The Antiemetic Efficacy of Aprepitant in Patients with Advanced Non-small-cell Lung Cancer Who Are Treated with Pemetrexed and Carboplatin. *Japanese Journal of Lung Cancer*, **2015**, 55, 1065-1069 0.1
- 36 A substantial investigation of discrepancy between patient complaints and assessment by medical personnel in chemotherapy-induced nausea. *Palliative Care Research*, **2015**, 10, 142-148 0.1
- 35 Delayed Nausea/Emesis. **2016**, 139-162
- 34 Clinical Management of CINV. **2016**, 157-162
- 33 A Pharmacocybernetics Approach to Patient Safety. **2016**, 1445-1464
- 32 Neurokinin-1 receptor antagonists for prevention of chemotherapy-related nausea and vomiting in adults. *The Cochrane Library*, 5.2
- 31 A Pharmacocybernetics Approach to Patient Safety. **2017**, 1291-1310
- 30 Supportive Care in Paediatric Oncology. **2018**, 89-107
- 29 Evaluation of the effectiveness of aprepitant for prevention of nausea and vomiting in patients with breast cancer. *Meditinskiy Sovet*, **2018**, 116-121 0.4
- 28 Nebenwirkungen und Komplikationen der medikamentösen Schmerztherapie. **2019**, 143-174
- 27 Measures for Adverse Events and Outpatient Chemotherapy of S-1+Cisplatin for Unresectable Progressive Recurrent Gastric Cancer. *Nihon Ika Daigaku Igakkai Zasshi*, **2019**, 15, 128-133 0
- 26 Endocrine and Metabolic Disorders after Hematopoietic Cell Transplantation. *Turkish Journal of Haematology*, **2020**, 37, 111-115 0.9 1
- 25 Adverse effect of chemotherapy. *Onkologie (Czech Republic)*, **2020**, 14, 13-17 0.1
- 24 The prevention and treatment of chemotherapy-induced nausea and vomiting in children and adolescents receiving cancer treatment: the current status and possibilities for improvement. *Pediatric Hematology/Oncology and Immunopathology*, **2020**, 19, 205-223 0.3 0
- 23 ERKRANKUNGEN DES BLUTES UND DES GERINNINGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE. **2020**, B-1-B30-3
- 22 [Prevention and treatment of antineoplastic drug-induced nausea and vomiting in pediatric onco-hematology: An update]. *Bulletin Du Cancer*, **2020**, 107, 800-812 2.4 0
- 21 Acupuncture for the Side Effects of Cancer Treatments. **2008**, 201-211

20 Prophylaxe und Therapie zytostatikainduzierten Erbrechens. 1350-1367

19 Prinzipien der konservativen Therapie. **2007**, 277-282

18 Supportive Treatment. **2008**, 204-292

17 Allgemeine onkologische Chemotherapie. **2014**, 689-709

16 Cannabis et cancer : à la veille de lâExpérimentation franãise du cannabis thãapeutique, de quelles donnès disposons-nous sur ses propriëtã thãapeutiques et ses dangers ?. *Psycho-oncologie*, **2020**, 14, 97-105

15 The Quality of Quality-of-Life and Cost-Effectiveness Analyses. *Gastrointestinal Cancer Research: GCR*, **2008**, 2, 94-5

14 Use of granisetron transdermal system in the prevention of chemotherapy-induced nausea and vomiting: a review. *Cancer Management and Research*, **2009**, 2, 1-12

13 Prevention of acute chemotherapy-induced nausea and vomiting: the role of palonosetron. *Cancer Management and Research*, **2009**, 1, 89-97

12 Aprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting. *Core Evidence*, **2007**, 2, 15-30

11 Ginger as a miracle against chemotherapy-induced vomiting. *Iranian Journal of Nursing and Midwifery Research*, **2012**, 17, 325-9

10 Effect of increase in duration of aprepitant consumption from 3 to 6 days on the prevention of nausea and vomiting in women receiving combination of anthracycline/cyclophosphamide chemotherapy: A randomized, crossover, clinical trial. *Advanced Biomedical Research*, **2015**, 4, 238

9 Efficacy of ondansetron against emesis induced by a multiple-day cisplatin-based chemotherapy regimen for malignant lymphoma. *Hematology*, **2021**, 26, 945-949

8 Gastric side effects and the stomach dosimetric analysis in left-sided breast cancer radiotherapy in free-breathing and deep inspiration breath-hold technique.. *Radiation Oncology*, **2022**, 17, 2

7 The role of the collagen gel droplet embedded culture-drug sensitivity test (CD-DST) to assess the sensitivity to chemo drugs for gastric cancer in combination with other cancer therapeutic drugs.. *Journal of Nippon Medical School*, **2022**,

6 Emetic Response to T-2 Toxin Correspond to Secretion of Glucagon-like Peptide-17ã6 Amide and Glucose-Dependent Insulinotropic Polypeptide. *Toxins*, **2022**, 14, 389

5 Sacituzumab Govitecan in Hormone ReceptorãPositive/Human Epidermal Growth Factor Receptor 2ãNegative Metastatic Breast Cancer.

4 Evaluation of Sex Differences in the Potential of ð-Tetrahydrocannabinol, Cannabidiol, Cannabidiolic Acid, and Oleoyl Alanine to Reduce Nausea-Induced Conditioned Gaping Reactions in Sprague-Dawley Rats.

3 The development of a novel antioxidant-based antiemetic drug to improve quality of life during anticancer therapy. **2022**, 32, 101363

2 Palliative care and quality of life. **2023**, 560-593.e8

o

1 Oral Therapies for Multiple Myeloma. **2022**, 18, 139

o